You are here

Publications

La technologie et les produits d’Angiochem sont fréquemment mentionnés dans la littérature scientifique et lors des colloques. Pour accéder à ces articles, affiches et exposés, cliquez sur les liens ci-dessous.

Vous devez posséder Adobe Acrobat Reader pour visualiser ces fichiers. Vous pouvez télécharger cette application gratuitement ici >

Peer-Reviewed Publications

Angiochem Publications

Demeule M et al. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties

Drappazt et al. Phase I Study of GRN1005 in Recurrent Malignant Glioma

Kurzrock, R. et al. Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors. Molecular Cancer Therapeutics, 12/2/2011.

Bertrand, Y, et.al, Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1, British Journal of Cancer (2011) 105, 1697 – 1707

Demeule M, et al. Involvement of the low-density lipoprotein receptorrelated protein in the transcytosis of the brain delivery vector Angiopep-2. J Neurochem 2008 10.1111/j.1471-4159.2008.05492.x

Demeule M, et al. Identification and Design of Peptides as a New Drug Delivery System for the Brain, JPET 324:1064-1072, 2008.

Turcotte S, et al. Roles of the Multidrug Resistance Transporter PGlycoprotein. From: Blood Brain Barriers - From ontogeny to artificial interfaces, Dermeitzel R, Spray DS, Nedergaard M, eds. 2006.

Demeule M, et al. Brain Endothelial Cells as Pharmacological Targets in Brain Tumors. Mol Neurobiol 30:157-183, 2004.

Demeule M, et al. Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vasc Pharmacol 38:339-348, 2002.

Regina A, et al. Multidrug resistance in brain tumors: Roles of the blood-brain barrier. Cancer and Metastasis Reviews 20:13-25, 2001.

Regina A, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol 2008, 1-13.

Thomas FC. Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer. Pharm Res 2009 26(11): 2486-94

Che C, et al. New Angiopep-Modified Doxorubicin (ANG1007) and Etoposide (ANG1009) Chemotherapeutics With Increased Brain Penetration. J Med Chem, 2010, 53 (7), 2814-2824.

External Academic Group

Angiopep-2-conjugated liposomes encapsulating c-secretase inhibitor for targeting glioblastoma stem cells

Synthesis of a ‘‘clickable’’ Angiopep-conjugated p-coumaric acid for brain-targeted delivery

Angiopep-2-Mediated Delivery of Human Manganese Superoxide Dismutase in Brain Endothelial Cells and its Protective Effect Against Oxidative Stress

Fluorescent Carbonaceous Nanodots for Noninvasive Glioma Imaging after Angiopep?2 Decoration

Angiopep-Conjugated Electro-Responsive Hydrogel Nanoparticles: Therapeutic Potential for Epilepsy

A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein

Dual targeting effect of Angiopep-2-modified, DNA-loaded nanoparticles for glioma

Two-Order Targeted Brain Tumor Imaging By Using An Optical/ Paramagnetic Nanoprobe across the Blood Brain Barrier

Retro-Inverso Isomer of Angiopep-2: A Stable D?Peptide Ligand Inspires Brain-Targeted Drug Delivery

Angiopep?2 and Activatable Cell-Penetrating Peptide Dual- Functionalized Nanoparticles for Systemic Glioma-Targeting Delivery

Angiopep-2 and activatable cell penetrating peptide dual modified nanoparticles for enhanced tumor targeting and penetrating

Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas

Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles

Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome

Angiopep-conjugated poly(ethylene glycol)-co-poly(e-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma

Publications on the Blood-Brain Barrier

Jones AR, Shusta EV. Blood-Brain Barrier Transport of Therapeutics via Receptor-Mediation. Pharm Res. 2007 September; 24(9): 1759-1.

Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacology & Therapeutics 104 (2004) 29-45.

Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Advanced Drug Delivery Reviews 36 (1999) 179-194.

Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiology of Disease 37 (2010) 48–57.

Deeken JF, Loscher W. The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses. Clin Cancer Res 2007;13(6) 1663-1674.

Posters and Presentations

Society of Neuroscience Meeting 2014

AACR congress 2014

San Antonio Breast Cancer Symposium 2013

AACR-NCI-EORTC Congress 2013

TIDES Meeting 2013

Neuroscience 2012, October 13-17, 2010, New Orleans, LA, USA

AACR/NCI/EORTC Annual Meeting, November 15, 2011, SF, CA

Neurosciences 2010, November 13-17, 2010, San Diego, CA, USA.

EORTC-NCI-AACR Annual Meeting 2009, Boston, MA, November 15-19, 2009

Society for Neuroscience Annual Meeting, Chicago, IL, USA, 17/21-Oct-2009

American Association for Cancer Research (AACR) 100th annual meeting, Denver, Colorado, USA, 18/22-Apr-2009

International Brain Barriers/Neuroscience Meeting, Gleneden Beach, Oregon, USA, 19/21-Mar-2009.

SOT 48th Annual Meeting, Baltimore, USA, 15/19 Mar-2009 (for SOT posters)

Society for Neuro-Oncology Annual Meeting, Las Vegas, Nevada, USA, 21/22-Nov-2008

Neuroscience 2008, Washington DC, USA, 18-Nov-2008

EORTC-NCI-AACR Annual Meeting 2008, Geneva, Switzerland, October 22/23, 2008